ライフサイエンスコーパス: total bilirubin

1 lar with regard to age, prothrombin time and total bilirubin.

2 serum creatinine, and (5) preoperative serum total bilirubin.

3 nces between groups were seen with Pi-GST or total bilirubin.

4 s a safe and efficacious method for reducing total bilirubin.

5 LP), gamma-glutamyl transpeptidase (GGT), or total bilirubin.

6 ne aminotransferase elevation plus increased total bilirubin.

7 5.2 vs 861.8 +/- 813.7 U/L; p </= 0.01), and total bilirubin (0.13 +/- 0.05 vs 0.30 +/- 0.14 mg/dL; p

8 activity (897 +/- 84 vs. 876 +/- 95, P =.5), total bilirubin (0.9 +/- 0.1 vs. 1 +/- 0.1, P =.07), asp

9 d ratio [1.2, P < 0.001; 1.1, P = 0.001] and total bilirubin (2.7, P = 0.001; 2.1, P = 0.05)).

10 cant decline in albumin levels and increased total bilirubin; 3 experienced duodenal or colonic bleed

11 alized ratio (1.5 and 1.2, respectively) and total bilirubin (4.6 and 2.7) were significantly greater

12 e 892 U/L, alkaline phosphatase 358 U/L, and total bilirubin 6.1 mg/dL.

13 ars), and they had elevated median values of total bilirubin (6.67 mg/dL), alanine aminotransferase (

14 ubin variation, was strongly associated with total bilirubin (a 0.68-SD increase in bilirubin levels

15 minotransferase (ALT), alkaline phosphatase, total bilirubin, albumin, creatinine, and hemoglobin; pr

16 or size, tumor capsule, pathological grades, total bilirubin, albumin, prothrombin time, alpha-fetopr

17 minotransferase, aspartate aminotransferase, total bilirubin, alkaline phosphatase, gamma-glutamyl tr

18 e, plasma lipids or the lipoprotein profile, total bilirubin, alkaline phosphatase, serum aspartate a

19 gh WBC count, raised serum ALT, raised serum total bilirubin and a lack of endoscopy were independent

20 Mean serum total bilirubin and alanine aminotransferase level on se

21 Current median follow-up values for total bilirubin and aspartate aminotransferase levels in

22 cellent: current median follow-up values for total bilirubin and aspartate aminotransferase were 0.5

23 ratified into four groups according to serum total bilirubin and AST and were treated with escalating

24 ak was located at chromosome 2q37.1 for both total bilirubin and direct bilirubin, with 29 SNPs reach

25 her levels of serum alkaline phosphatase and total bilirubin and lower levels of total cholesterol an

26 95% CI, 1.03 to 1.08 per 1 mg/dl increase in total bilirubin) and metabolic acidosis (RR, 0.95; 95% C

27 biochemical (e.g., alkaline phosphatase, and total bilirubin), and clinical evaluation was combined w

28 erase, alanine aminotransferase, bile acids, total bilirubin), and increased KC expression of interle

29 [AST]/alanine aminotransferase [ALT] ratio, total bilirubin, and albumin) with three categories of c

30 tional normalized ratio of prothrombin time, total bilirubin, and creatinine).

31 aminotransferase, alanine aminotransferase, total bilirubin, and gamma glutamyl transferase were hig

32 se severity based on serum creatinine, serum total bilirubin, and INR and has been shown to be useful

33 lower albumin, lower platelet count, higher total bilirubin, and more advanced Ishak fibrosis score

34 d decreased plasma alanine aminotransferase, total bilirubin, and serum alkaline phosphatase levels b

35 Lower platelet count and higher total bilirubin at 2 years were significantly associated

36 ne variables lower platelet count and higher total bilirubin at 2 years were significantly associated

37 serum levels of alanine aminotransferase and total bilirubin at presentation were independent risk fa

38 t cirrhosis had significantly higher initial total bilirubin at the onset of histologic recurrence an

39 In a subgroup with total bilirubin between 2 and 6 mg/dL at 3 months after

40 s for an increase in alanine transaminase or total bilirubin between both CSL112 arms and placebo was

41 Median total bilirubin, CA19-9, and carcinoembryonic antigen (C

42 n neurotoxicity than the conventionally used total bilirubin concentration (BT).

43 o clear) were then utilized to calculate the total bilirubin concentration.

44 in plasma samples from patients with similar total bilirubin concentrations but varying levels of con

45 survival after adjustments for age, gender, total bilirubin, creatinine, prothrombin time, and diagn

46 Over the same interval total bilirubin declined by a median of 70 mumol/L (p <

47 Serum total bilirubin decreased after PEBD in FIC1 (8.1 +/- 4.

48 ides the capabilities to not only quantitate total bilirubin (Deming-regression slope of 0.95, R(2) =

49 ed in 4 patients, of which 1 had concomitant total bilirubin elevation.

50 patients in the deferred treatment group had total bilirubin elevations.

51 Total bilirubin for the above-normal group was 2.1+/-0.9

52 ard designed to measure the concentration of total bilirubin from several drops of blood at the point

53 tate transaminase, alanine transaminase, and total bilirubin) function in 309 (235 male, 74 female) a

54 mg/dL or less, compared to 36% in those with total bilirubin greater than 1.3 mg/dL.

55 acteristics: ascites, esophageal varices, or total bilirubin greater than 2 mg/dL.

56 ient survival than patients converted with a total bilirubin > 10 mg/dl (P=0.00002 and P=0.00125, res

57 dehydrogenase > 500 international units and total bilirubin > 3.0 mg/dL or serum transaminase level

58 patients with recent surgery, malignancy, or total bilirubin > 34 micromol/L (> 2 mg/dl).

59 ze > or =8 mm on admission ultrasound, serum total bilirubin > or = 1.7 mg/dL, or serum amylase > or

60 CLIF-C ACLFs) and presence of liver failure (total bilirubin >/=12 mg/dL) at ACLF diagnosis.

61 the upper limit of normal or an increase in total bilirubin >2 times the upper limit of normal) or a

62 tio >1.5 or transaminases >5 times normal or total bilirubin >3 mg/dL; and needing mechanical ventila

63 ction (severe, mild-moderate vs. normal) and total bilirubin (>/= 2.0, 0.6 to <2.0 vs. <0.6 mg/dL).

64 transferase (HR 4.22, p 0.016), raised serum total bilirubin (HR 5.79, p 0.008) and lack of an endosc

65 eks after BDL significantly lowers the serum total bilirubin in both groups.

66 lot clinical study using BiliSpec to measure total bilirubin in neonates at risk for jaundice at Quee

67 elevated levels of alanine transaminase and total bilirubin in patients receiving TACE plus RT compa

68 The mean serum total bilirubin in the adult population is 0.62 +/- 0.00

69 0%), and grade 1 or 2 elevation in levels of total bilirubin (in 12%), alkaline phosphatase (in 21%),

70 Compared with fresh RBCs, mean serum total bilirubin increased by 0.55 mg/dL at 4 hours after

71 Total bilirubin increased slightly after transplantation

72 y atresia patients were inversely related to total bilirubin, indicating that extrahepatic bile duct

73 elded 6 parameters of interest: age <1 year, total bilirubin, international normalized ratio (INR), a

74 endpoints were successful surgical drainage (total bilirubin less than 2 mg/dL within the first 3 mon

75 Significant liver insufficiency (total bilirubin level > 10 mg/dL or international normal

76 aminotransferase level >1000 U/L (P = .027), total bilirubin level >7 mg/dL (P = .036), and IL28B.rs1

77 per liter; P<0.001 for both comparisons) and total bilirubin level (-0.02 and -0.05 mg per deciliter

78 cromol/L, alanine aminotransferase 4079 U/L, total bilirubin level 11.4 mg/dl, and glucose 70 mg/dl (

79 splant recipients with metastatic NETs whose total bilirubin level at transplantation was 1.3 mg/dL o

80 increased significantly with elevated serum total bilirubin level at transplantation.

81 The mean total bilirubin level for the responder group was 7.1 mg

82 ion risk factors for adverse outcomes in AC: total bilirubin level greater than 10 mg/dL and white bl

83 ll count greater than 20000 cells/microL and total bilirubin level greater than 10 mg/dL are independ

84 latelet count 100,000/microL or greater, and total bilirubin level less than 1.5 mg/dL.

85 he platelet count of 205 (x 10(9)/L) and the total bilirubin level of 1.7 mg/dL were the best cutoff

86 the percentage of participants with a serum total bilirubin level of less than 1.5 mg/dL with his/he

87 ds ratio, 3.4; 95% CI, 1.2-9.5; P = .02) and total bilirubin level of more than 10 mg/dL (odds ratio,

88 c insufficiency was peak postoperative serum total bilirubin level of more than 7 mg/dL or, in jaundi

89 The mean serum total bilirubin level of the study patients was 2.28 mg/

90 to study a potential causal effect of serum total bilirubin level on T2D risk.

91 Total bilirubin level was elevated by 2-fold in the Slco

92 tide decile, glomerular filtration rate, and total bilirubin level were included in a simplified mode

93 the plasma PfHRP2 level, parasitemia level, total bilirubin level, and RCD at a shear stress of 1.7

94 of at least 15% from baseline, and a normal total bilirubin level.

95 undice was diagnosed in patients with plasma total bilirubin levels >3 mg/dL.

96 Pretreatment total bilirubin levels (mean +/- standard deviation) wer

97 UGT1A1 genotype and total bilirubin levels are strongly associated with seve

98 ped cholestasis with significantly increased total bilirubin levels at day 7 (16 +/- 5.2 mg% vs. 3.7

99 1 U/L), but similar alkaline phosphatase and total bilirubin levels compared with HCV-negative patien

100 Serum total bilirubin levels in healthy patients reflect genet

101 rovement Network) with measurements of serum total bilirubin levels recorded 3 months before the firs

102 to tacrolimus before development of elevated total bilirubin levels showed a significant impact on lo

103 es from baseline in alkaline phosphatase and total bilirubin levels that differed significantly from

104 In ATP11C-deficient mice, plasma total bilirubin levels were 6-fold increased, compared t

105 se, serum glutamic pyruvic transaminase, and total bilirubin levels, was significantly lower in the e

106 ) 99mTc-mebrofenin adjusted to the patients' total bilirubin levels.

107 raging and may be related to the increase in total bilirubin levels.

108 nder, baseline albumin >/=3.5 g/dL, baseline total bilirubin </=1.2 mg/dL, absence of cirrhosis, and

109 R12 were higher albumin (>/=3.5 g/dL), lower total bilirubin (</=1.2 g/dL), absence of cirrhosis, and

110 Serum total bilirubin may serve as a predictor of poor posttra

111 zard ratio, 0.46; P<0.0001) and preoperative total bilirubin (mg/dL; hazard ratio, 1.26; P=0.0002) we

112 Creatinine, total bilirubin, minority ethnicity, graft under-sizing,

113 sferase greater than three times the ULN and total bilirubin more than twice the ULN) after treatment

114 Patients with a total bilirubin of < or = 10 mg/dl at the time of conver

115 At baseline, the cases had a total bilirubin of 2.2 mg/dL, alanine aminotransferase o

116 Average total bilirubin on postoperative day 5 was 4.9 mg/dl.

117 y abnormalities in alanine aminotransferase, total bilirubin, or hemoglobin were observed.

118 n posttransplant alanine aminotransferase or total bilirubin, or the risk of intraoperative death and

119 portional hazards analysis was conducted and total bilirubin (P < 0.001, hazard ratio [HR] = 2.09, 95

120 ase (p = .009), creatinine kinase (p = .01), total bilirubin (p = .05), and plasma concentrations of

121 e attenuated after additional adjustment for total bilirubin (P = 0.08 and 0.02), which increased fro

122 ut transitory improvement in serum levels of total bilirubin (P =.001) and a significant, but margina

123 .03), foam cell clusters (P<0.01) and higher total bilirubin (P<0.02) and aspartate aminotransferase

124 posttransplant alanine aminotransferase and total bilirubin, primary nonfunction, and 30-day and 1-y

125 e above variables, in addition to donor age, total bilirubin, prothrombin time (PT), retransplantatio

126 the onset of histologic recurrence and peak total bilirubin (pT.Bili, the highest value in the ensui

127 crofluidic level for the ultimate purpose of total bilirubin quantitation.

128 Prothrombin time (PT), total bilirubin, serum ammonia, and hepatic encephalopat

129 Total bilirubin (T-Bil) is an important clinical diagnos

130 Total bilirubin (TB) and direct bilirubin (dB), hematocr

131 )Ugt1(-/-) mice expressed elevated levels of total bilirubin (TB) compared with Tg(UGT1(A1*1))Ugt1(-/

132 An alkaline phosphatase (AP) to total bilirubin (TB) ratio <4 yielded a sensitivity of 9

133 ansferase (ALT), alkaline phosphatase (AST), total bilirubin (TBIL) and direct bilirubin (DBIL) with

134 t (PSG) was decreased to normal level, while total bilirubin (TBIL) and liver function were significa

135 levels of alanine aminotransferase (ALT) and total bilirubin (TBL).

136 enotype had a statistically greater baseline total bilirubin than patients with 6/6 or 6/7 genotype (

137 ion analysis demonstrated that pretransplant total bilirubin, UNOS status, and graft type significant

138 of 0.97 (R(2) = 0.960) when compared to the total bilirubin values determined in the clinical labora

139 en tested in univariate models, pretreatment total bilirubin was able to modify the existing associat

140 Total bilirubin was elevated abnormally in 56 of 111 pat

141 ompared with twice-daily HDAC given when the total bilirubin was less than 2.0 mg/dL (33% v 14%; P =

142 splant values for recipient age, weight, and total bilirubin were 1.4 years, 12.3 kg, and 13.8 mg/dL,

143 Peak and discharge total bilirubin were 8.1+/-0.9 and 2.5+/-0.5 mg/dl.

144 Age, AST, AST/ALT ratio, and total bilirubin were identified as significant predictor

145 median levels of prothrombin time, INR, and total bilirubin were, respectively, 33% (Q1-Q3, 21-41),

146 nts were not significantly different, except total bilirubin, which was lower in the FK arm (P=0.02).

147 (AST), gamma-glutamyltransferase (GGT), and total bilirubin, which-in combination-attenuated the reg

148 eemed to distinguish different phenotypes of total bilirubin within the TA indel genotypes.